Trader’s Buzzers: Xerox Corporation (XRX), ARIAD Pharmaceuticals, Inc. (ARIA), Exxon Mobil Corporation (XOM)

Xerox Corporation (XRX) traded within a range of $6.93 to $7.04 after opening the day at $6.94. The company has seen its stock increase in value by 22.09% so far this year. The stock was up close to 1.3% on light volume in last trading session and closed at $7.02 per share. After the recent gain, the stock is currently holding -4.06% below its 52 week high of $11.39 and 29.81% above its 12-month low of $6.46. The shares are up by over 12.31% in the last three months, and the RSI indicator value of 65.65 is neither bullish nor bearish, tempting investors to stay on the sidelines.

Xerox Corporation provides business process and document management solutions worldwide. Its Services segment offers business process outsourcing services, such as customer care, transaction processing, finance and accounting, human resources, communication and marketing, and consulting and analytics services, as well as services in the areas of healthcare, transportation, financial services, retail, and telecommunications areas. This segment also provides document outsourcing services comprising managed print services, including workflow automation and centralized print services. The company’s Document Technology segment offers desktop monochrome and color printers, multifunction printers, copiers, digital printing presses, and light production devices; and production printing and publishing systems for the graphic communications marketplace and large enterprises. Its Other segment sells paper, wide-format systems, global imaging systems network integration solutions, and electronic presentation systems. The company sells its products and services directly to its customers; and through its sales force, as well as through a network of independent agents, dealers, value-added resellers, systems integrators, and the Web. Xerox Corporation was founded in 1906 and is headquartered in Norwalk, Connecticut.

ARIAD Pharmaceuticals, Inc. (ARIA) managed to rebound with the stock climbing 0.23% or $0.06 to close the day at $23.7 on active trading volume of 11.93M shares, compared to its three month average trading volume of 10.24M. The Cambridge Massachusetts 02139 based company has been outperforming the biotechnology group over the past 52 weeks, with the stock gaining 349.62%, compared to the industry which has advanced 3.8% over the same period. With RSI of 89.74, the stock should still continue to rise and get closer to its one year target estimate of $20.63, making it a hold for now.

ARIAD Pharmaceuticals, Inc., an oncology company, engages in the discovery, development, and commercialization of drugs for cancer patients in the United States and internationally. It offers Iclusig (ponatinib), a tyrosine kinase inhibitor (TKI) for the treatment of adult patients with chronic myeloid leukemia (CML), and Philadelphia chromosome-positive acute lymphoblastic leukemia in the United States, the European Union, Australia, Switzerland, Israel, and Canada. The company also develops Brigatinib, an investigational inhibitor of anaplastic lymphoma kinase for the treatment of various patients with a form of non-small cell lung cancer; and AP32788, for treating non-small cell lung cancer and various other solid tumors. It markets and sells Iclusig through specialty pharmacy in the United States. The company has license agreements with Medinol Ltd. to develop and commercialize stents and other medical devices to deliver ridaforolimus. ARIAD Pharmaceuticals, Inc. was founded in 1991 and is headquartered in Cambridge, Massachusetts.

Exxon Mobil Corporation (XOM) dropped $-1.08 to close the day at a new closing price of $86.28, a -1.24% decrease in value from its previous closing price that moved the stock 24.85% above its 52 week low of $72.61. A total of 11.79M shares exchanged hands during the day compared with its three month average trading volume of 10.78M. The stock, which fluctuated between $86.05 and $87.41 during the day, currently situated -8.13% below its 52 week high. The stock is down by -5.07% in the past one month and up by 0.58% over the past three months. With a one year target estimate of $88.64 and RSI of 39.16, the stock still has upside potential, making it a hold for now.

Exxon Mobil Corporation explores for and produces crude oil and natural gas in the United States, Canada/South America, Europe, Africa, Asia, and Australia/Oceania. It also manufactures and markets commodity petrochemicals, including olefins, aromatics, polyethylene and polypropylene plastics, and specialty products; and transports and sells crude oil, natural gas, and petroleum products. As of December 31, 2015, the company had approximately 35,909 gross and 30,114 net operated wells. Exxon Mobil Corporation was founded in 1870 and is headquartered in Irving, Texas.

 

Investor’s Alert: WPX Energy, Inc. (WPX), Exxon Mobil Corporation (XOM), ARIAD Pharmaceuticals, Inc. (ARIA)

WPX Energy, Inc. (WPX) managed to rebound with the stock climbing 2.84% or $0.39 to close the day at $14.11 on lower than average trading volume of 13.84M shares, compared to its three month average trading volume of 7.92M. The Tulsa Oklahoma 74172 based company has been outperforming the independent oil & gas companies by 13.4637% for last three months and its recent gains have offset losses to -3.16% YTD, versus the independent oil & gas industry which is up 0.18% for the same period. The RSI of 48.23 indicates the stock is neither overvalued nor undervalued at the current levels, hold for now.

WPX Energy, Inc., an independent oil and natural gas exploration and production company, engages in the exploitation and development of unconventional properties in the United States. Its principal areas of operation include the Permian Basin in Texas and New Mexico, the Williston Basin in North Dakota, and the San Juan Basin in New Mexico and Colorado. As of December 31, 2014, the company had proved reserves of 583 million barrels of oil equivalent. WPX Energy, Inc. was incorporated in 2011 and is headquartered in Tulsa, Oklahoma.

Exxon Mobil Corporation (XOM) had a active trading with around 13.21M shares changing hands compared to its three month average trading volume of 10.66M. The stock traded between $86.25 and $87.39 before closing at the price of $87.36 with 1.17% change on the day. The Irving Texas 75039 based company is currently trading 26.41% above its 52 week low of $71.55 and -6.98% below its 52 week high of $95.55. Both the RSI indicator and target price of 43.5 and $88.64 respectively, lead us to believe that it should be put on hold over the coming weeks.

Exxon Mobil Corporation explores for and produces crude oil and natural gas in the United States, Canada/South America, Europe, Africa, Asia, and Australia/Oceania. It also manufactures and markets commodity petrochemicals, including olefins, aromatics, polyethylene and polypropylene plastics, and specialty products; and transports and sells crude oil, natural gas, and petroleum products. As of December 31, 2015, the company had approximately 35,909 gross and 30,114 net operated wells. Exxon Mobil Corporation was founded in 1870 and is headquartered in Irving, Texas.

ARIAD Pharmaceuticals, Inc. (ARIA) opening the day at $23.67. The company has seen its stock increase in value by 90.03% so far this year. The stock was down close to -0.21% on active volume in last trading session and closed at $23.64 per share. After the recent fall, the stock is currently holding -0.71% below its 52 week high of $23.81 and 440.96% above its 12-month low of $4.37. The shares are up by over 112.21% in the last three months, and the RSI indicator value of 89.41 is bearish. The technical indicator is offering a warning sign that the stock can’t keep current pace going.

ARIAD Pharmaceuticals, Inc., an oncology company, engages in the discovery, development, and commercialization of drugs for cancer patients in the United States and internationally. It offers Iclusig (ponatinib), a tyrosine kinase inhibitor (TKI) for the treatment of adult patients with chronic myeloid leukemia (CML), and Philadelphia chromosome-positive acute lymphoblastic leukemia in the United States, the European Union, Australia, Switzerland, Israel, and Canada. The company also develops Brigatinib, an investigational inhibitor of anaplastic lymphoma kinase for the treatment of various patients with a form of non-small cell lung cancer; and AP32788, for treating non-small cell lung cancer and various other solid tumors. It markets and sells Iclusig through specialty pharmacy in the United States. The company has license agreements with Medinol Ltd. to develop and commercialize stents and other medical devices to deliver ridaforolimus. ARIAD Pharmaceuticals, Inc. was founded in 1991 and is headquartered in Cambridge, Massachusetts.

 

Eye Catching Stocks: Xerox Corporation (XRX), ARIAD Pharmaceuticals, Inc. (ARIA), Delta Air Lines, Inc. (DAL)

Xerox Corporation (XRX) continued its downward trend with the stock declining -0.86% or $-0.06 to close the day at $6.94 on active trading volume of 14.92M shares, compared to its three month average trading volume of 11.9M. The Norwalk Connecticut 06856 based company has been outperforming the information technology services group over the past 52 weeks, with the stock gaining 18.03%, compared to the industry which has advanced 23.68% over the same period. With RSI of 66.84, the stock should still continue to rise and get closer to its one year target estimate of $9.83, making it a hold for now.

Xerox Corporation provides business process and document management solutions worldwide. Its Services segment offers business process outsourcing services, such as customer care, transaction processing, finance and accounting, human resources, communication and marketing, and consulting and analytics services, as well as services in the areas of healthcare, transportation, financial services, retail, and telecommunications areas. This segment also provides document outsourcing services comprising managed print services, including workflow automation and centralized print services. The company’s Document Technology segment offers desktop monochrome and color printers, multifunction printers, copiers, digital printing presses, and light production devices; and production printing and publishing systems for the graphic communications marketplace and large enterprises. Its Other segment sells paper, wide-format systems, global imaging systems network integration solutions, and electronic presentation systems. The company sells its products and services directly to its customers; and through its sales force, as well as through a network of independent agents, dealers, value-added resellers, systems integrators, and the Web. Xerox Corporation was founded in 1906 and is headquartered in Norwalk, Connecticut.

ARIAD Pharmaceuticals, Inc. (ARIA) climbed 0.04% during last trading as the stock added $0.01 to finish the day at $23.71 with about 14.66M shares changing hands, compared to its three month average trading volume of 10.08M. The $4.49B market cap company, which fluctuated between $23.68 and $23.71 during the day, currently situated 442.56% above its 52 week low of $4.37 and -0.42% away from its one year high of $23.71. The RSI of 90.44 indicates the stock is overbought at the current levels, sell for now.

ARIAD Pharmaceuticals, Inc., an oncology company, engages in the discovery, development, and commercialization of drugs for cancer patients in the United States and internationally. It offers Iclusig (ponatinib), a tyrosine kinase inhibitor (TKI) for the treatment of adult patients with chronic myeloid leukemia (CML), and Philadelphia chromosome-positive acute lymphoblastic leukemia in the United States, the European Union, Australia, Switzerland, Israel, and Canada. The company also develops Brigatinib, an investigational inhibitor of anaplastic lymphoma kinase for the treatment of various patients with a form of non-small cell lung cancer; and AP32788, for treating non-small cell lung cancer and various other solid tumors. It markets and sells Iclusig through specialty pharmacy in the United States. The company has license agreements with Medinol Ltd. to develop and commercialize stents and other medical devices to deliver ridaforolimus. ARIAD Pharmaceuticals, Inc. was founded in 1991 and is headquartered in Cambridge, Massachusetts.

Delta Air Lines, Inc. (DAL) saw its value decrease by -1.07% as the stock dropped $-0.55 to finish the day at a closing price of $50.89. The stock was higher in trading and has fluctuated between $32.6-$52.76 per share for the past year. The shares, which traded within a range of $49.67 to $52 during the day, are up by 30.19% in the past three months and up by 25.44% over the past six months. It is currently trading 1.58% above its 20 day moving average and 5.31% above its 50 day moving average. Analysts believe the company can continue to increase in value to reach at $59.07 a share over the next twelve months. The current relative strength index (RSI) reading is 58.32. The technical indicator lead us to believe there will be no major movement any time soon, hold.

Delta Air Lines, Inc. provides scheduled air transportation for passengers and cargo in the United States and internationally. The company operates through two segments, Airline and Refinery. Its route network is centered around a system of hubs, international gateways, and airports in Amsterdam, Atlanta, Boston, Detroit, London-Heathrow, Los Angeles, Minneapolis-St. Paul, New York-LaGuardia, New York-JFK, Paris-Charles de Gaulle, Salt Lake City, Seattle, and Tokyo-Narita. The company sells its tickets through various distribution channels, including delta.com and mobile, telephone reservations, traditional brick and mortar, and online travel agencies. It also provides aircraft maintenance, repair, and overhaul services; staffing, and professional security and training services, as well as aviation solutions to third parties; vacation packages to third-party consumers; and aircraft charters, and aircraft management and programs. As of February 3, 2016, the company operated a fleet of approximately 800 aircrafts. Delta Air Lines, Inc. was founded in 1924 and is headquartered in Atlanta, Georgia.

 

3 Stocks in Focus: ARIAD Pharmaceuticals, Inc. (ARIA), Ford Motor Company (F), Freeport-McMoRan Inc. (FCX)

ARIAD Pharmaceuticals, Inc. (ARIA) fell -0.29% during last trading as the stock lost $-0.07 to finish the day at $23.68 with about 62.15M shares changing hands, compared to its three month average trading volume of 8.71M. The $4.48B market cap company, currently situated 441.88% above its 52 week low of $4.37 and -0.55% away from its one year high of $23.79. The RSI of 90.79 indicates the stock is overbought at the current levels, sell for now.

ARIAD Pharmaceuticals, Inc., an oncology company, engages in the discovery, development, and commercialization of drugs for cancer patients in the United States and internationally. It offers Iclusig (ponatinib), a tyrosine kinase inhibitor (TKI) for the treatment of adult patients with chronic myeloid leukemia (CML), and Philadelphia chromosome-positive acute lymphoblastic leukemia in the United States, the European Union, Australia, Switzerland, Israel, and Canada. The company also develops Brigatinib, an investigational inhibitor of anaplastic lymphoma kinase for the treatment of various patients with a form of non-small cell lung cancer; and AP32788, for treating non-small cell lung cancer and various other solid tumors. It markets and sells Iclusig through specialty pharmacy in the United States. The company has license agreements with Medinol Ltd. to develop and commercialize stents and other medical devices to deliver ridaforolimus. ARIAD Pharmaceuticals, Inc. was founded in 1991 and is headquartered in Cambridge, Massachusetts.

Ford Motor Company (F) gained $0.22 to close the day at a new closing price of $12.85, a 1.74% increase in value from its previous closing price that moved the stock 20.67% above its 52 week low of $11.02. A total of 58.56M shares exchanged hands during the day compared with its three month average trading volume of 35.29M. The stock, which fluctuated between $12.66 and $13.02 during the day, currently situated -7.51% below its 52 week high. The stock is down by -1.38% in the past one month and up by 7.34% over the past three months. With a one year target estimate of $12.74 and RSI of 57.49, the stock still has upside potential, making it a hold for now.

Ford Motor Company, together with its subsidiaries, designs, manufactures, markets, finances, and services automobiles. The company operates through two sectors, Automotive and Financial Services. The Automotive sector develops, manufactures, distributes, and services passenger cars, trucks, SUVs, light commercial vehicles, trucks, vans, and electrified vehicles, as well as offers parts and accessories. It offers vehicles primarily under the Ford and Lincoln brand names. This sector markets and sells its products through distributors and dealers, as well as through dealerships to fleet customers, including commercial fleet customers, daily rental car companies, and governments. The Financial Services sector offers various automotive financing products to and through automotive dealers. It provides financing products, including retail installment sale contracts for new and used vehicles; and direct financing leases for new vehicles to retail and commercial customers, government entities, daily rental car companies, leasing companies, and fleet customers. This sector also offers wholesale loans to dealers to finance the purchase of vehicle inventory; and loans to dealers to finance working capital and improvement of dealership facilities, purchase dealership real estate, and other dealer vehicle programs. It serves clients in North America, South America, Europe, the Middle East, Africa, and the Asia Pacific. Ford Motor Company was founded in 1903 and is based in Dearborn, Michigan.

Freeport-McMoRan Inc. (FCX) had a active trading with around 44.01M shares changing hands compared to its three month average trading volume of 32.31M. The stock traded between $15.22 and $15.73 before closing at the price of $15.55 with 5.93% change on the day. The Phoenix Arizona 85004 based company is currently trading 341.76% above its 52 week low of $3.52 and -5.3% below its 52 week high of $16.42. Both the RSI indicator and target price of 63.2 and $13.14 respectively, lead us to believe that it should be put on hold over the coming weeks.

Freeport-McMoRan Inc., a natural resource company, acquires, explores, and develops mineral assets, and oil and natural gas resources. The company explores for copper, gold, molybdenum, cobalt hydroxide, silver, and other metals, as well as oil and gas. It holds interests in various mines located in the Grasberg minerals district in Indonesia; Morenci, Bagdad, Safford, Sierrita, Miami, Chino, Tyrone, Henderson, and Climax in North America; Cerro Verde and El Abra in South America; and the Tenke Fungurume minerals district in the Democratic Republic of Congo, Africa. The company’s oil and gas operations include oil production facilities in the Deepwater Gulf of Mexico; oil production facilities onshore and offshore in California; onshore natural gas resources in the Haynesville shale in Louisiana; natural gas production from the Madden area in central Wyoming; and a position in the Inboard Lower Tertiary/Cretaceous natural gas trend onshore located in South Louisiana. As of December 31, 2015, its consolidated recoverable proven and probable mineral reserves included 99.5 billion pounds of copper, 27.1 million ounces of gold, 3.05 billion pounds of molybdenum, 271.2 million ounces of silver, and 0.87 billion pounds of cobalt; and its estimated proved oil and natural gas reserves totaled 252 million barrels of oil equivalents. The company was formerly known as Freeport-McMoRan Copper & Gold Inc. and changed its name to Freeport-McMoRan Inc. in July 2014. Freeport-McMoRan Inc. was founded in 1987 and is headquartered in Phoenix, Arizona.

 

Trader Alert: ARIAD Pharmaceuticals, Inc. (ARIA), Ascena Retail Group, Inc. (ASNA), Viacom, Inc. (VIAB)

ARIAD Pharmaceuticals, Inc. (ARIA) grew with the stock adding 2.54% or $0.34 to close at $13.74 on light trading volume of 4.21M compared its three months average trading volume of 6.59M. The Cambridge Massachusetts 02139 based company operating under the Biotechnology industry has been trending up for the last 52 weeks, with the shares price now 161.22% up for the period and up by 10.45% so far this year. With price target of $13.45 and a 214.42% rebound from 52-week low, ARIAD Pharmaceuticals, Inc. has plenty of upside potential, making it a hold with a view buy.

ARIAD Pharmaceuticals, Inc., an oncology company, engages in the discovery, development, and commercialization of drugs for cancer patients in the United States and internationally. It offers Iclusig (ponatinib), a tyrosine kinase inhibitor (TKI) for the treatment of adult patients with chronic myeloid leukemia (CML), and Philadelphia chromosome-positive acute lymphoblastic leukemia in the United States, the European Union, Australia, Switzerland, Israel, and Canada. The company also develops Brigatinib, an investigational inhibitor of anaplastic lymphoma kinase for the treatment of various patients with a form of non-small cell lung cancer; and AP32788, for treating non-small cell lung cancer and various other solid tumors. It markets and sells Iclusig through specialty pharmacy in the United States. The company has license agreements with Medinol Ltd. to develop and commercialize stents and other medical devices to deliver ridaforolimus. ARIAD Pharmaceuticals, Inc. was founded in 1991 and is headquartered in Cambridge, Massachusetts.

Ascena Retail Group, Inc. (ASNA) dropped $-0.04 to close the day at a new closing price of $6, a -0.66% decrease in value from its previous closing price that moved the stock 28.21% above its 52 week low of $4.68. A total of 4.2M shares exchanged hands during the day compared with its three month average trading volume of 4.65M. The stock, which fluctuated between $5.79 and $6.12 during the day, currently situated -46.71% below its 52 week high. The stock is down by -18.59% in the past one month and up by 4.71% over the past three months. With a one year target estimate of $7.7 and RSI of 40.94, the stock still has upside potential, making it a hold for now.

Ascena Retail Group, Inc., through its subsidiaries, operates as a specialty retailer of apparel, shoes, and accessories for women and tween girls in the United States, Canada, and Puerto Rico. The company operates through six segments: ANN, Justice, Lane Bryant, maurices, dressbarn, and Catherines. It creates, designs, and develops a range of merchandise, including apparel, accessories, footwear, and intimates; lifestyle products comprising cosmetics, bedroom furnishings, and electronics; and wear-to-work, casual sportswear, footwear, and social occasion apparel. The company also offers casual clothing, career wear, dressy apparel, and active wear, as well as special occasion and classic apparel. Its principal brands comprise ANN TAYLOR, LOFT, ANN TAYLOR LOFT, LOU & GREY, JUSTICE, LANE BRYANT, LANE BRYANT OUTLET, CACIQUE, RIGHT FIT, MAURICES, DRESSBARN, CATHERINES, CATHERINES PLUS SIZES, MAGGIE BARNES, LIZ&ME, SERENADA, DRESSBAR, 6th & LANE, and MAURICES IN MOTION. As of July 30, 2016, the company operated approximately 4,900 stores. It also offers its products through its Websites, including anntaylor.com, LOFT.com, louandgrey.com, shopjustice.com, lanebryant.com, cacique.com, maurices.com, dressbarn.com, and catherines.com. The company was formerly known as Dress Barn, Inc. and changed its name to Ascena Retail Group, Inc. in January 2011. Ascena Retail Group, Inc. was founded in 1962 and is based in Mahwah, New Jersey.

Viacom, Inc. (VIAB) shares were up in last trading by 0.83% to $37.79. It experienced higher than average volume on day. The stock increased in value by almost 7.11% over the past week and grew 4.02% in the past month. It is currently trading 3.12% above its 50 day moving average and -3.97% below its 200 day moving average. Following the recent increase in price, the stock’s new closing price represents a -18.14% decrease in value from its one year high of $47.47. The RSI indicator value of 62.61, lead us to believe that it is a hold for now.

Viacom, Inc. operates as media brand worldwide. The company creates television programs, motion pictures, short-form content, applications, games, consumer products, social media experiences, and other entertainment content for audiences. It operates through two segments, Media Networks and Filmed Entertainment. The Media Networks segment provides entertainment content and related branded products for consumers through approximately 250 locally programmed and operated TV channels, including Nickelodeon, Comedy Central, MTV, VH1, SPIKE, BET, CMT, TV Land, Nick at Nite, Nick Jr., Channel 5 (UK), Logo, Nicktoons, TeenNick, Paramount Channel, and others, as well as through online, mobile, and apps. The Filmed Entertainment segment produces, finances, acquires, and distributes motion pictures, television programming, and other entertainment content under the Paramount Pictures, Paramount Animation, Nickelodeon Movies, MTV Films, and Paramount Television brands; and distributes films released under the Paramount Vantage, Paramount Classics, and Insurge Pictures brands. This segment exhibits motion pictures theatrically through home entertainment, licensing to television and digital platforms, and ancillary activities. The company releases its content through download-to-own, download-to-rent, DVDs, Blu-ray discs, transactional video-on-demand, pay television, subscription video-on-demand, basic cable television, free television, and free video-on-demand, as well as airlines and hotels. Viacom, Inc. is headquartered in New York, New York.

 

Trader’s Buzzers: JetBlue Airways Corporation (JBLU), Pepsico, Inc. (PEP), ARIAD Pharmaceuticals, Inc. (ARIA)

JetBlue Airways Corporation (JBLU) traded within a range of $22.11 to $22.67 after opening the day at $22.66. The company has seen its stock decrease in value by -0.67% so far this year. The stock was down close to -1.68% on light volume in last trading session and closed at $22.27 per share. After the recent fall, the stock is currently holding -5.91% below its 52 week high of $23.67 and 50.88% above its 12-month low of $14.76. The shares are up by over 24.69% in the last three months, and the RSI indicator value of 61.05 is neither bullish nor bearish, tempting investors to stay on the sidelines.

JetBlue Airways Corporation, a passenger carrier company, provides air transportation services. As of December 31, 2014, the company operated a fleet of 25 Airbus A321 aircrafts, 130 Airbus A320 aircrafts, and 60 Embraer E190 aircrafts. It also served 93 destinations in 28 states in the United States, the District of Columbia, the Commonwealth of Puerto Rico, the U.S. Virgin Islands, and 19 countries in the Caribbean and Latin America. JetBlue Airways Corporation was founded in 1998 and is based in Long Island City, New York.

Pepsico, Inc. (PEP) failed to extend gains with the stock declining -0.13% or $-0.14 to close the day at $104.71 on active trading volume of 4.61M shares, compared to its three month average trading volume of 4.36M. The Purchase New York 10577 based company has been outperforming the beverages – soft drinks group over the past 52 weeks, with the stock gaining 8.36%, compared to the industry which has advanced 4.08% over the same period. With RSI of 51.95, the stock should still continue to rise and get closer to its one year target estimate of $116.85, making it a hold for now.

PepsiCo, Inc. operates as a food and beverage company worldwide. Its Frito-Lay North America segment offers Lay’s and Ruffles potato chips; Doritos, Tostitos and Santitas tortilla chips; and Cheetos cheese-flavored snacks, branded dips, and Fritos corn chips. The company’s Quaker Foods North America segment provides Quaker oatmeal, grits, rice cakes, natural granola, and oat squares; and Aunt Jemima mixes and syrups, Quaker Chewy granola bars, Cap’n Crunch cereal, Life cereal, and Rice-A-Roni side dishes. Its North America Beverages segment offers beverage concentrates, fountain syrups, and finished goods under the Pepsi, Gatorade, Mountain Dew, Diet Pepsi, Aquafina, Diet Mountain Dew, Tropicana Pure Premium, Sierra Mist, and Mug brands; and ready-to-drink tea and coffee, and juices. The company’s Latin America segment provides snack foods under the Doritos, Cheetos, Marias Gamesa, Ruffles, Emperador, Saladitas, Sabritas, Lay’s, Rosquinhas Mabel, and Tostitos brands; cereals and snacks under the Quaker brand; and beverage concentrates, fountain syrups, and finished goods under the Pepsi, 7UP, Gatorade, Mirinda, Diet 7UP, Manzanita Sol, and Diet Pepsi brands. Its Europe Sub-Saharan Africa segment offers snack foods under the Lay’s, Walkers, Doritos, Cheetos, and Ruffles brands; cereals and snacks under the Quaker brand; beverage concentrates, fountain syrups, and finished goods under the Pepsi, 7UP, Pepsi Max, Mirinda, Diet Pepsi, and Tropicana brands; ready-to-drink tea products; and dairy products under the Chudo, Agusha, and Domik v Derevne brands. The company’s Asia, Middle East and North Africa segment provides snack foods under the Lay’s, Kurkure, Chipsy, Doritos, Cheetos, and Crunchy brands; cereals and snacks under the Quaker brand; beverage concentrates, fountain syrups, and finished goods under the Pepsi, Mirinda, 7UP, Mountain Dew, Aquafina, and Tropicana brands; and tea products. The company was founded in 1898 and is headquartered in Purchase, New York.

ARIAD Pharmaceuticals, Inc. (ARIA) gained $0.34 to close the day at a new closing price of $13.4, a 2.6% increase in value from its previous closing price that moved the stock 206.64% above its 52 week low of $4.37. A total of 4.57M shares exchanged hands during the day compared with its three month average trading volume of 6.6M. The stock, which fluctuated between $12.82 and $13.47 during the day, currently situated -7.07% below its 52 week high. The stock is up by 0.9% in the past one month and down by -3.39% over the past three months. With a one year target estimate of $13.45 and RSI of 66.23, the stock still has upside potential, making it a hold for now.

ARIAD Pharmaceuticals, Inc., an oncology company, engages in the discovery, development, and commercialization of drugs for cancer patients in the United States and internationally. It offers Iclusig (ponatinib), a tyrosine kinase inhibitor (TKI) for the treatment of adult patients with chronic myeloid leukemia (CML), and Philadelphia chromosome-positive acute lymphoblastic leukemia in the United States, the European Union, Australia, Switzerland, Israel, and Canada. The company also develops Brigatinib, an investigational inhibitor of anaplastic lymphoma kinase for the treatment of various patients with a form of non-small cell lung cancer; and AP32788, for treating non-small cell lung cancer and various other solid tumors. It markets and sells Iclusig through specialty pharmacy in the United States. The company has license agreements with Medinol Ltd. to develop and commercialize stents and other medical devices to deliver ridaforolimus. ARIAD Pharmaceuticals, Inc. was founded in 1991 and is headquartered in Cambridge, Massachusetts.

 

Stocks Trend Analysis: CVS Health Corporation (CVS), ACADIA Pharmaceuticals Inc. (ACAD), ARIAD Pharmaceuticals, Inc. (ARIA)

CVS Health Corporation (CVS) failed to extend gains with the stock declining -0.75% or $-0.6 to close the day at $79.75 on light trading volume of 7.1M shares, compared to its three month average trading volume of 8.35M. The Woonsocket Rhode Island 02895 based company has been underperforming the health care plans group over the past 52 weeks, with the stock losing -16.07%, compared to the industry which has advanced 6.6% over the same period. With RSI of 51.91, the stock should still continue to rise and get closer to its one year target estimate of $87.1, making it a hold for now.

CVS Health Corporation, together with its subsidiaries, provides integrated pharmacy health care services. It operates through Pharmacy Services and Retail/LTC segments. The Pharmacy Services segment offers pharmacy benefit management solutions, such as plan design and administration, formulary management, Medicare Part D services, mail order and specialty pharmacy services, retail pharmacy network management services, prescription management systems, clinical services, disease management programs, and medical pharmacy management services. This segment serves employers, insurance companies, unions, government employee groups, health plans, managed Medicaid plans and plans offered on public and private exchanges, other sponsors of health benefit plans, and individuals under the CVS Caremark Pharmacy Services, Caremark, CVS Caremark, CarePlus CVS Pharmacy, CVS Specialty, Accordant, SilverScript, NovoLogix, Coram, Navarro Health Services, and Advanced Care Scripts names. As of December 31, 2015, it operated 24 retail specialty pharmacy stores, 11 specialty mail order pharmacies and 5 mail order dispensing pharmacies, and 83 branches for infusion and enteral services. The Retail/LTC segment sells prescription drugs, over-the-counter drugs, beauty products and cosmetics, personal care products, convenience foods, seasonal merchandise, and greeting cards, as well as provides photo finishing services. It operates 9,655 retail stores in 49 states, the District of Columbia, Puerto Rico, and Brazil primarily under the CVS Pharmacy, CVS, Longs Drugs, Navarro Discount Pharmacy, and Drogaria Onofre names; online retail pharmacy Websites; and 32 onsite pharmacy stores, long-term care pharmacy operations, and retail health care clinics. The company was formerly known as CVS Caremark Corporation and changed its name to CVS Health Corporation in September 2014. CVS Health Corporation was founded in 1892 and is headquartered in Woonsocket, Rhode Island.

ACADIA Pharmaceuticals Inc. (ACAD) grew with the stock adding 11.02% or $3.17 to close at $31.94 on active trading volume of 7.01M compared its three months average trading volume of 2.67M. The company operating under the Biotechnology industry has been trending down for the last 52 weeks, with the shares price now -7.31% down for the period and up by 10.75% so far this year. With price target of $41.73 and a 91.95% rebound from 52-week low, ACADIA Pharmaceuticals Inc. has plenty of upside potential, making it a hold with a view buy.

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. Its lead product candidate, NUPLAZID, has completed the Phase III pivotal trials for the treatment of Parkinson’s disease psychosis and the Phase II trial for the treatment of schizophrenia, as well as is in Phase II study for the treatment of Alzheimer’s disease psychosis. It also has clinical-stage programs for glaucoma and, in collaboration with Allergan, Inc., for chronic pain. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.

ARIAD Pharmaceuticals, Inc. (ARIA) managed to rebound with the stock climbing 5.58% or $0.69 to close the day at $13.06 on higher than average trading volume of 6.99M shares, compared to its three month average trading volume of 6.57M. The Cambridge Massachusetts 02139 based company has been outperforming the biotechnology companies by -2.2709% for last three months and its recent losses have trimmed gains to 4.98% YTD, versus the biotechnology industry which is up 2.5% for the same period. The RSI of 63.04 indicates the stock is neither overvalued nor undervalued at the current levels, hold for now.

ARIAD Pharmaceuticals, Inc., an oncology company, engages in the discovery, development, and commercialization of drugs for cancer patients in the United States and internationally. It offers Iclusig (ponatinib), a tyrosine kinase inhibitor (TKI) for the treatment of adult patients with chronic myeloid leukemia (CML), and Philadelphia chromosome-positive acute lymphoblastic leukemia in the United States, the European Union, Australia, Switzerland, Israel, and Canada. The company also develops Brigatinib, an investigational inhibitor of anaplastic lymphoma kinase for the treatment of various patients with a form of non-small cell lung cancer; and AP32788, for treating non-small cell lung cancer and various other solid tumors. It markets and sells Iclusig through specialty pharmacy in the United States. The company has license agreements with Medinol Ltd. to develop and commercialize stents and other medical devices to deliver ridaforolimus. ARIAD Pharmaceuticals, Inc. was founded in 1991 and is headquartered in Cambridge, Massachusetts.

 

Investor’s Watch List: Fastenal Company (FAST), ARIAD Pharmaceuticals, Inc. (ARIA), W&T Offshore, Inc. (WTI)

Fastenal Company (FAST) had a active trading with around 2.83M shares changing hands compared to its three month average trading volume of 2.71M. The stock traded at the price of $46.95 with -0.06% change on the day. The Winona Minnesota 55987 based company is currently trading 37.76% above its 52 week low of $35.1 and -4.79% below its 52 week high of $49.99. Both the RSI indicator and target price of 53.5 and $44.56 respectively, lead us to believe that it should be put on hold over the coming weeks.

Fastenal Company, together with its subsidiaries, engages in the wholesale distribution of industrial and construction supplies in the United States, Canada, and internationally. It offers fasteners, and other industrial and construction supplies primarily under the Fastenal name. The company’s fastener products include threaded fasteners, such as bolts, nuts, screws, studs, and related washers, which are used in manufactured products and building projects, as well as in the maintenance and repair of machines and structures. It also offers miscellaneous supplies and hardware, including various pins and machinery keys, concrete anchors, metal framing systems, wire ropes, strut products, rivets, and related accessories. The company serves the manufacturing market comprising original equipment manufacturers, maintenance, repair, and operations; and non-residential construction market, which include general, electrical, plumbing, sheet metal, and road contractors. It also serves farmers, truckers, railroads, mining companies, schools, and retail trades; and oil exploration, production, and refinement companies, as well as federal, state, and local governmental entities. The company distributes its products through a network of approximately 2,600 company owned stores. Fastenal Company was founded in 1967 and is headquartered in Winona, Minnesota.

ARIAD Pharmaceuticals, Inc. (ARIA) failed to extend gains with the stock declining -0.56% or $-0.07 to close the day at $12.37 on light trading volume of 2.83M shares, compared to its three month average trading volume of 6.59M. The Cambridge Massachusetts 02139 based company has been outperforming the biotechnology group over the past 52 weeks, with the stock gaining 100.81%, compared to the industry which has dropped -6.22% over the same period. With RSI of 53.93, the stock should still continue to rise and get closer to its one year target estimate of $13.45, making it a hold for now.

ARIAD Pharmaceuticals, Inc., an oncology company, engages in the discovery, development, and commercialization of drugs for cancer patients in the United States and internationally. It offers Iclusig (ponatinib), a tyrosine kinase inhibitor (TKI) for the treatment of adult patients with chronic myeloid leukemia (CML), and Philadelphia chromosome-positive acute lymphoblastic leukemia in the United States, the European Union, Australia, Switzerland, Israel, and Canada. The company also develops Brigatinib, an investigational inhibitor of anaplastic lymphoma kinase for the treatment of various patients with a form of non-small cell lung cancer; and AP32788, for treating non-small cell lung cancer and various other solid tumors. It markets and sells Iclusig through specialty pharmacy in the United States. The company has license agreements with Medinol Ltd. to develop and commercialize stents and other medical devices to deliver ridaforolimus. ARIAD Pharmaceuticals, Inc. was founded in 1991 and is headquartered in Cambridge, Massachusetts.

W&T Offshore, Inc. (WTI) shares were up in last trading by 2.89% to $2.85. It experienced higher than average volume on day. The stock decreased in value by almost -1.72% over the past week and grew 35.71% in the past month. It is currently trading 47.58% above its 50 day moving average and 42.39% above its 200 day moving average. Following the recent increase in price, the stock’s new closing price represents a -18.57% decrease in value from its one year high of $3.5. The RSI indicator value of 69.15, lead us to believe that it is a hold for now.

W&T Offshore, Inc., an independent oil and natural gas producer, engages in the acquisition, exploration, and development of oil and natural gas properties in the Gulf of Mexico. The company sells crude oil, natural gas liquids, and natural gas. It holds working interests in approximately 54 offshore fields in federal and state waters. As of March 8, 2016, the company had interests in offshore leases covering approximately 900,000 gross acres, including approximately 550,000 gross acres in the Gulf of Mexico Shelf; and approximately 350,000 gross acres in the deepwater. It also has a total proved reserves of 76.4 million barrels of oil equivalent. The company was founded in 1983 and is headquartered in Houston, Texas.

 

3 Stocks in Focus: Five Below, Inc. (FIVE), Cousins Properties Incorporated (CUZ), ARIAD Pharmaceuticals, Inc. (ARIA)

Five Below, Inc. (FIVE) climbed 2.17% during last trading as the stock added $0.85 to finish the day at $39.96 with about 2.52M shares changing hands, compared to its three month average trading volume of 1.23M. The $2.15B market cap company, which fluctuated between $38.7 and $40.41 during the day, currently situated 27.02% above its 52 week low of $31.46 and -24.17% away from its one year high of $52.7. The RSI of 51.55 indicates the stock is neither overvalued nor undervalued at the current levels, hold for now.

Five Below, Inc. operates as a specialty value retailer in the United States. It offers accessories, including novelty socks, sunglasses, jewelry, scarves, gloves, hair accessories, athletic tops and bottoms, and T-shirts, as well as beauty products comprising nail polish, lip gloss, fragrance, and branded cosmetics; and items used to complete and personalize living space, including glitter lamps, posters, frames, fleece blankets, pillows, candles, incense, and related items, as well as provides storage options for the customer’s room and locker. The company also provides sport balls; team sports merchandise and fitness accessories, such as hand weights, jump ropes, and gym balls; games, including name brand board games, puzzles, toys, and plush items; and pool, beach and outdoor toys, games, and accessories. In addition, it offers accessories, such as cases, chargers, headphones, and other related items for PCs, cell phones, and tablet computers; books, video games, and DVDs; craft activity kits; arts and crafts supplies that consist of crayons, markers, and stickers; and trend-right items for school comprising backpacks, fashion notebooks and journals, novelty pens and pencils, and everyday name brand items. Further, the company provides party goods, decorations, and greeting cards, as well as every day and special occasion merchandise products; assortment of classic and novelty candy bars, movie-size box candy, and gum and snack food; chilled drinks through coolers; and seasonally-specific items used to celebrate and decorate for events, such as Christmas, Easter, Halloween, and St. Patrick’s Day. It primarily serves teen and pre-teen customers. As of December 1, 2016, it operated approximately 517 stores in 31 states. The company was formerly known as Cheap Holdings, Inc. and changed its name to Five Below, Inc. in August 2002. Five Below, Inc. was founded in 2002 and is headquartered in Philadelphia, Pennsylvania.

Cousins Properties Incorporated (CUZ) gained $0.19 to close the day at a new closing price of $8.51, a 2.28% increase in value from its previous closing price that moved the stock 20.03% above its 52 week low of $7.09. A total of 2.51M shares exchanged hands during the day compared with its three month average trading volume of 4.72M. The stock, which fluctuated between $8.26 and $8.56 during the day, currently situated -25.35% below its 52 week high. The stock is up by 7.59% in the past one month and down by -18.49% over the past three months. With a one year target estimate of $8.5 and RSI of 62.34, the stock still has upside potential, making it a hold for now.

Cousins Properties Incorporated, a real estate investment trust (REIT), owns, develops, and manages real estate portfolio, as well as performs certain real estate-related services in the United States. The company operates through four divisions: Office/Multi-Family, Retail, Industrial, and Land. The Office/Multi-Family division develops and manages office projects primarily in Austin, Dallas, Charlotte, Birmingham, and Atlanta; develops and sells multi-family projects in urban locations in the southeastern United States; and manages and leases office properties owned by third parties. It also develops mixed use projects that contain multiple product types in communities where individuals live, work, and seek entertainment. As of December 31, 2006, this division owned interests in 20 operating office properties; and had 5 office or multi-family projects under development or redevelopment. The Retail division develops and manages retail shopping centers principally in Georgia, Tennessee, North Carolina, Texas, and Florida. As of the above date, this division owned 10 operating retail properties; and had 3 projects and 1 expansion under development. The Industrial division develops institutional warehouse and distribution properties in the metropolitan Atlanta area and the Dallas market. As of December 31, 2006, this division owned one operating industrial property and three projects under development. The Land division engages in the acquisition and entitlement of land, the development and sale of residential lots, and the acquisition and sale of certain undeveloped tracts of land to third parties. As of the above date, this division had 24 residential communities under development. The company qualifies as a REIT under the Internal Revenue Code. As a REIT, it would not be subject to federal corporate income taxes, if it distributes at least 90% of its taxable income to its stockholders. Cousins Properties was founded in 1958 and is based in Atlanta, Georgia.

ARIAD Pharmaceuticals, Inc. (ARIA) had a light trading with around 2.5M shares changing hands compared to its three month average trading volume of 6.7M. The stock traded between $12.37 and $12.6 before closing at the price of $12.44 with 0.32% change on the day. The Cambridge Massachusetts 02139 based company is currently trading 184.67% above its 52 week low of $4.37 and -13.73% below its 52 week high of $14.42. Both the RSI indicator and target price of 54.11 and $13.45 respectively, lead us to believe that it should be put on hold over the coming weeks.

ARIAD Pharmaceuticals, Inc., an oncology company, engages in the discovery, development, and commercialization of drugs for cancer patients in the United States and internationally. It offers Iclusig (ponatinib), a tyrosine kinase inhibitor (TKI) for the treatment of adult patients with chronic myeloid leukemia (CML), and Philadelphia chromosome-positive acute lymphoblastic leukemia in the United States, the European Union, Australia, Switzerland, Israel, and Canada. The company also develops Brigatinib, an investigational inhibitor of anaplastic lymphoma kinase for the treatment of various patients with a form of non-small cell lung cancer; and AP32788, for treating non-small cell lung cancer and various other solid tumors. It markets and sells Iclusig through specialty pharmacy in the United States. The company has license agreements with Medinol Ltd. to develop and commercialize stents and other medical devices to deliver ridaforolimus. ARIAD Pharmaceuticals, Inc. was founded in 1991 and is headquartered in Cambridge, Massachusetts.

 

Trader’s Round Up: ARIAD Pharmaceuticals, Inc. (ARIA), Ares Capital Corporation (ARCC), FMC Technologies, Inc. (FTI)

ARIAD Pharmaceuticals, Inc. (ARIA) retreated with the stock falling -1.35% or $-0.17 to close at $12.4 on light trading volume of 2.28M compared its three months average trading volume of 6.75M. The Cambridge Massachusetts 02139 based company operating under the Biotechnology industry has been trending up for the last 52 weeks, with the shares price now 95.58% up for the period and up by 98.4% so far this year. With price target of $13.45 and a 183.75% rebound from 52-week low, ARIAD Pharmaceuticals, Inc. has plenty of upside potential, making it a hold with a view buy.

ARIAD Pharmaceuticals, Inc., an oncology company, engages in the discovery, development, and commercialization of drugs for cancer patients in the United States and internationally. It offers Iclusig (ponatinib), a tyrosine kinase inhibitor (TKI) for the treatment of adult patients with chronic myeloid leukemia (CML), and Philadelphia chromosome-positive acute lymphoblastic leukemia in the United States, the European Union, Australia, Switzerland, Israel, and Canada. The company also develops Brigatinib, an investigational inhibitor of anaplastic lymphoma kinase for the treatment of various patients with a form of non-small cell lung cancer; and AP32788, for treating non-small cell lung cancer and various other solid tumors. It markets and sells Iclusig through specialty pharmacy in the United States. The company has license agreements with Medinol Ltd. to develop and commercialize stents and other medical devices to deliver ridaforolimus. ARIAD Pharmaceuticals, Inc. was founded in 1991 and is headquartered in Cambridge, Massachusetts.

Ares Capital Corporation (ARCC) gained $0.34 to close the day at a new closing price of $16.56, a 2.1% increase in value from its previous closing price that moved the stock 48.84% above its 52 week low of $12.31. A total of 2.28M shares exchanged hands during the day compared with its three month average trading volume of 2.33M. The stock, currently situated -0.12% below its 52 week high. The stock is up by 5.75% in the past one month and up by 9.59% over the past three months. With a one year target estimate of $16.68 and RSI of 69.1, the stock still has upside potential, making it a hold for now.

FMC Technologies, Inc. (FTI) shares were up in last trading by 1.02% to $35.55. It experienced lighter than average volume on day. The stock increased in value by almost 1.69% over the past week and grew 7.73% in the past month. It is currently trading 4.24% above its 50 day moving average and 21.22% above its 200 day moving average. Following the recent increase in price, the stock’s new closing price represents a -2.63% decrease in value from its one year high of $36.51. The RSI indicator value of 56.77, lead us to believe that it is a hold for now.

FMC Technologies, Inc., together with its subsidiaries, designs, manufactures, and services technological systems and products for customers in the energy industry worldwide. It operates through Subsea Technologies, Surface Technologies, and Energy Infrastructure segments. The Subsea Technologies segment offers subsea systems for the offshore production of crude oil and natural gas; and installation, asset management, product optimization, and well access and intervention services, as well as inspection, maintenance, and repair services. This segment also provides electric and hydraulic work-class remotely operating vehicle, tether-management, launch and recovery, remote manipulator arms, and modular control systems for subsea applications, as well as support services, such as product training, pilot simulator training, spare parts, and technical assistance; and offers multiphase and wetgas meters to measure production rates of oil, water, and gas for topside and subsea applications. The Surface Technologies segment offers wellhead systems for standard and custom-engineered applications; fluid control products for the well completion and stimulation activities; and flowback, cased hole electric wireline and slickline, specialty logging, and well optimization services. The Energy Infrastructure segment provides measurement products, such as flow computers and control systems, and gas and liquid measurement systems, as well as floating production, storage, and off-loading metering systems; and design, engineering, project management, training, commissioning, and aftermarket services. This segment also offers land- and marine-based loading and transfer systems for ship-to-ship loading and offloading operations; systems that separate production flows from wells into oil, gas, sand, and water; and automation, control, and information technology services. FMC Technologies, Inc. was founded in 2000 and is headquartered in Houston, Texas.